Fierce Biotech

AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan

Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...

AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
Analytics Insight

Cyberattack on AstraZeneca Sparks Global Security Concerns, Stolen Data Surfaces on Dark Web

A major cyberattack has targeted pharmaceutical giant AstraZeneca. Hackers claim they stole internal company data and later ...
Seeking Alpha

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and ...
The Economist

AstraZeneca’s falling out with Britain

IN A COUNTRY struggling to find reasons for cheer, British life sciences offer a ray of hope. The £108bn ($145bn) industry employs more than 300,000 people, many in high-value jobs, and Britain is a ...

AstraZeneca drug reduces COPD flare-ups in late-stage trials

March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...